Stockreport

Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst [Seeking Alpha]

Aldeyra Therapeutics, Inc.  (ALDX) 
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aldeyra.com/investor-relations
PDF Reproxalap's Chamber Phase 3 trial met symptom endpoints with rapid, durable relief. However, the main risk is that the field trial missed the primary symptom endpoin [Read more]